GlaxoSmithKline received approval from the FDA for its sBLA for unadjuvanted influenza A (H1N1) pandemic vaccine. The approval, which was filed as a strain change supplement to GSK’s FluLaval seasonal flu vaccine, allows the company to manufacture a flu vaccine for use in adults to prevent the 2009 pandemic H1N1 influenza A strain. The United States Department of Health and Human Services has placed an order to fill 7.6 million doses of the vaccine.The vaccine will be produced in multi-dose v...